CN109259243A - Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application - Google Patents
Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application Download PDFInfo
- Publication number
- CN109259243A CN109259243A CN201811125403.3A CN201811125403A CN109259243A CN 109259243 A CN109259243 A CN 109259243A CN 201811125403 A CN201811125403 A CN 201811125403A CN 109259243 A CN109259243 A CN 109259243A
- Authority
- CN
- China
- Prior art keywords
- composition
- hypertension
- hyperglycemia
- parts
- lower hyperlipidemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 56
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 55
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 33
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 33
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 33
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 30
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 30
- 244000302512 Momordica charantia Species 0.000 claims abstract description 19
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 19
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 19
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 19
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 9
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 15
- 238000012216 screening Methods 0.000 claims description 14
- 235000013402 health food Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- 239000004383 Steviol glycoside Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 235000019411 steviol glycoside Nutrition 0.000 claims description 6
- 229930182488 steviol glycoside Natural products 0.000 claims description 6
- 150000008144 steviol glycosides Chemical class 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 27
- 230000036772 blood pressure Effects 0.000 abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 17
- 229920001184 polypeptide Polymers 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 13
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 12
- 230000000052 comparative effect Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 6
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 6
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710176384 Peptide 1 Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UDYXEHXKWCEKMT-FPAZSGHZSA-N N1[C@@H](CCC1)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O Chemical compound N1[C@@H](CCC1)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O UDYXEHXKWCEKMT-FPAZSGHZSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 230000001000 lipidemic effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
Abstract
The present invention provides compositions of a kind of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application.Wherein, the composition of lower hyperlipidemia, hypertension, hyperglycemia, the raw material components including following parts by weight: 1-6 parts of lactobacillus acidophilus, 1-6 parts of bifidobacterium lactis, the newborn polypeptide of 10-27 parts of peace benefits, 1-5 parts of balsam pear victory peptides and 72-105 parts of prebiotics.Each group distribution ratio is reasonable in above-mentioned composition, can play composition optimal efficacy, has the function of lowering blood pressure and blood fat and hypoglycemic.
Description
Technical field
The present invention relates to field of functional food, and in particular to a kind of composition of lower hyperlipidemia, hypertension, hyperglycemia and preparation method thereof and answers
With.
Background technique
With the improvement of living standards with the change of rhythm of life, the disease incidence of " three high diseases " is higher and higher, " three high diseases "
Refer to hypertension, hyperglycemia (diabetes) and hyperlipemia.Belong to cardiovascular and cerebrovascular disease, they are mainly that modern civilization derives
" rich people's disease " come, possible individualism, it is also possible to interrelated.Such as: diabetes patient be easy to suffer from simultaneously hypertension or
Hyperlipemia, and hyperlipidemia is the principal element of artery sclerosis formation and development, the aggravation of arteriosclerotic's blood vessel elasticity difference
Blood pressure increases.So there are any one of these three illness, the later period, all easily development formed " three high diseases ", especially in old age
People, body function decline person, disease incidence highest in hypoimmunity crowd.
Summary of the invention
Therefore, it is necessary to provide a kind of combination of lower hyperlipidemia, hypertension, hyperglycemia aiming at the problem that being susceptible to suffer from hypertension, hyperglycemia and high fat of blood
Object and its preparation method and application.
A kind of composition of lower hyperlipidemia, hypertension, hyperglycemia, the raw material components including following parts by weight:
Wherein, strain includes 1-6 parts of lactobacillus acidophilus, 1-6 parts of bifidobacterium lactis.
Each group distribution ratio is reasonable in above-mentioned composition, can play composition optimal efficacy, have lowering blood pressure and blood fat and
Hypoglycemic effect.Specifically, insulin sensitivity can be improved in lactobacillus acidophilus, to reduce blood glucose.Bifidobacterium lactis
Specific immunity is improved, disease is prevented.The newborn polypeptide of peace benefit is a kind of cardiovascular multifunctional polypeptide, is had to rising blood pressure
Angiotensin converting enzyme (ACE) rise inhibiting effect, pass through hinder make blood pressure rise enzyme, inhibit blood pressure rise.In addition, peace
Beneficial cream polypeptide can also improve blood vessel elasticity, be used for cardiovascular prevention and control.Balsam pear, which wins peptide, has reducing blood lipid, hypoglycemic effect.
Prebiotics can provide energy for lactobacillus acidophilus and bifidobacterium lactis, promote lactobacillus acidophilus and cream as dietary supplements
The growth and breeding of Bifidobacterium, while intestines peristalsis can also be promoted, it is edible such as old to be particularly suitable for stodgy crowd
People.In addition, above-mentioned composition also plays the role of prevention to hypertension, hyperglycemia, hyperlipidemia.
In one embodiment, further include the raw material components of following parts by weight:
The strain further include 1-6 parts of lactobacillus paracasei,
1-5 parts of balsam pear powder,
And 0.1-1 parts of steviol glycoside.
In one embodiment, the viable count 7.0 × 10 contained in the lactobacillus paracasei9-9.5×109CFU/g。
In one embodiment, the prebiotics are selected from one or both of galactooligosaccharide and oligofructose.
In one embodiment, the viable count contained in the lactobacillus acidophilus is 3.0 × 109-5.5×109CFU/g, institute
Stating the viable count contained in bifidobacterium lactis is 5.0 × 109-7.5×109CFU/g。
The present invention also provides a kind of preparation methods of the composition of lower hyperlipidemia, hypertension, hyperglycemia.
A kind of preparation method of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention, comprising the following steps:
Each raw material is taken according to corresponding parts by weight；
Other each raw materials in addition to strain are sieved respectively and obtain screening object；
It will screening object and strain mixing.
The preparation method of above-mentioned composition is simple, and the composition being prepared has the function of lower hyperlipidemia, hypertension, hyperglycemia.
In one embodiment, the sieving referred to 50-70 mesh, and interception partial size is less than the screening object of 50-70 mesh.
It in one embodiment, further include doing other each raw materials in addition to strain at 50 DEG C -70 DEG C before sieving
It is dry, up to the moisture content in other each raw materials in addition to strain is lower than 3%.
The present invention also provides a kind of health foods.
A kind of health food, acceptable auxiliary material on composition and food including lower hyperlipidemia, hypertension, hyperglycemia as described in the present application.
Above-mentioned health food has the function of lowering blood pressure and blood fat and hypoglycemic.
In one embodiment, the type of the health food is lozenge, chewable tablets or solid beverage.
Specific embodiment
In order to make the foregoing objectives, features and advantages of the present invention clearer and more comprehensible, below in conjunction with specific embodiment,
The present invention will be described in further detail.It should be appreciated that the specific embodiments described herein are only used to explain this hair
It is bright, it is not intended to limit the present invention.
Unless otherwise defined, all technical and scientific terms used herein and belong to technical field of the invention
The normally understood meaning of technical staff is identical.Term as used herein in the specification of the present invention is intended merely to description tool
The purpose of the embodiment of body, it is not intended that in the limitation present invention.
Raw materials used and reagent is commercially available common raw material and reagent unless otherwise specified in following embodiment.
The present invention provides a kind of compositions of lower hyperlipidemia, hypertension, hyperglycemia comprising the raw material components of following parts by weight:
Wherein, strain includes 1-6 parts of lactobacillus acidophilus, 1-6 parts of bifidobacterium lactis
Of course, it should be understood that other components can also be added in the raw material components of above-mentioned composition with enhance blood pressure lowering,
Reducing blood lipid and hypoglycemic effect.For example, sweetener, balsam pear powder etc. can be added.
Herein referred lower hyperlipidemia, hypertension, hyperglycemia refers to lowering blood pressure and blood fat and hypoglycemic.
Wherein, the newborn polypeptide of peace benefit is the raw material components of core in the composition.The newborn polypeptide of peace benefit is a kind of more function of angiocarpy
Energy peptide pacifies the newborn polypeptide of benefit by Val-Pro-Pro (valine-Proline-Proline), Ile-Pro-Pro (isoleucine-dried meat
Propylhomoserin-proline) two kinds of peptides constitute, also referred to as " newborn tripeptides ".With to the angiotensin converting enzyme for increase blood pressure
(ACE) inhibiting effect is played, by the enzyme for hindering increase blood pressure, blood pressure is inhibited to rise.In addition, the newborn polypeptide of peace benefit can also improve
Blood vessel elasticity is used for cardiovascular prevention and control.
Wherein, balsam pear victory peptide is the raw material components of another core in the composition, has reducing blood lipid, hypoglycemic function
Effect.
Wherein, lactobacillus acidophilus main function is to improve insulin sensitivity, to reduce blood glucose.
In a preferred embodiment, the viable count contained in the lactobacillus acidophilus is 3.0 × 109-5.5×109CFU/
g.Number of viable within this range can more preferably play the effect of lactobacillus acidophilus, insulin sensitivity be improved, to drop
Hypoglycemia.
Wherein, bifidobacterium lactis main function is to improve immunity, prevents disease.
In a preferred embodiment, the viable count contained in the bifidobacterium lactis is 5.0 × 109-7.5×109CFU/
g.Number of viable within this range can more preferably play the effect of bifidobacterium lactis, improve specific immunity, prevent disease
Disease occurs.
Wherein, prebiotics can provide energy for lactobacillus acidophilus and bifidobacterium lactis, promote thermophilic as dietary supplements
The growth and breeding of two kinds of probiotics of Lactobacillus lactis and bifidobacterium lactis, and then reduce blood glucose and strengthen immunity, while can also be with
Promote intestines peristalsis, is particularly suitable for stodgy crowd and eats, especially the elderly.
In a preferred embodiment, the prebiotics are selected from one or both of galactooligosaccharide and oligofructose,
Energy preferably can be provided for lactobacillus acidophilus and bifidobacterium lactis, promote the two growth and breeding, and then reduce blood glucose and increasing
Strong immunity.
In a preferred embodiment, the composition of the lower hyperlipidemia, hypertension, hyperglycemia includes the raw material components of following parts by weight:
In a preferred embodiment, the composition of the lower hyperlipidemia, hypertension, hyperglycemia includes the raw material components of following parts by weight:
Wherein, the main function of lactobacillus paracasei is to reduce blood glucose, reducing blood lipid, to prevent and treat cardiovascular disease
Disease.
In a preferred embodiment, the viable count 7.0 × 10 contained in the lactobacillus paracasei9-9.5×109CFU/
g。
Wherein, the effect of main function of balsam pear powder is hypoglycemic, reducing blood lipid.
In a preferred embodiment, the sweetener is preferably steviol glycoside.Composition can be enhanced in steviol glycoside
Mouthfeel is easy to consumer's receiving.
Each group distribution ratio is reasonable in above-mentioned composition, can play composition optimal efficacy, have lowering blood pressure and blood fat and
Hypoglycemic effect.Specifically, insulin sensitivity can be improved in lactobacillus acidophilus, to reduce blood glucose.Bifidobacterium lactis
Specific immunity is improved, disease is prevented.The newborn polypeptide of peace benefit is a kind of cardiovascular multifunctional polypeptide, is had to rising blood pressure
Angiotensin converting enzyme (ACE) rise inhibiting effect, pass through hinder make blood pressure rise enzyme, inhibit blood pressure rise.In addition, should
Peptide can also improve blood vessel elasticity, be used for cardiovascular prevention and control.Balsam pear, which wins peptide, has reducing blood lipid, hypoglycemic effect.Prebiotics
As dietary supplements, energy can be provided for lactobacillus acidophilus and bifidobacterium lactis, promote lactobacillus acidophilus and newborn bifid bar
The growth and breeding of bacterium, while intestines peristalsis can also be promoted, it is particularly suitable for stodgy crowd and eats, such as the elderly.When
So it is understood that above-mentioned composition also plays the role of prevention to hypertension, hyperglycemia, hyperlipidemia.
The present invention also provides a kind of preparation methods of the composition of lower hyperlipidemia, hypertension, hyperglycemia.
A kind of preparation method of the composition of lower hyperlipidemia, hypertension, hyperglycemia, comprising the following steps:
Each raw material is taken according to corresponding parts by weight, other each raw materials in addition to strain are sieved respectively and obtain screening object,
Then object will be screened and strain mixes the composition of lower hyperlipidemia, hypertension, hyperglycemia to obtain the final product.Wherein, screening object can be the newborn polypeptide of peace benefit, balsam pear victory peptide
With the compound of prebiotics composition, screening object can also be the newborn polypeptide of peace benefit, balsam pear victory peptide, prebiotics, balsam pear powder and stevioside
The compound of glycosides composition.Strain can be the combination of lactobacillus acidophilus and bifidobacterium lactis, strain be also possible to lactobacillus acidophilus,
The combination of bifidobacterium lactis and lactobacillus paracasei.
In a preferred embodiment, the sieving referred to 50-70 mesh, and interception partial size is less than the screening of 50-70 mesh
Object.Guarantee that the composition grain of lower hyperlipidemia, hypertension, hyperglycemia is uniform, to make the good in taste of product.
In a preferred embodiment, before sieving, further include by other each raw materials in addition to strain at 50 DEG C -70 DEG C
It is dry, up to the moisture content in other each raw materials in addition to strain is lower than 3%.Low moisture content can make the combination containing raw material
Object has the longer holding time, and lower moisture content can also guarantee the activity of strain in composition.
The preparation method of above-mentioned composition is simple, and the composition being prepared has the function of lower hyperlipidemia, hypertension, hyperglycemia.
The present invention also provides a kind of health foods comprising acceptable auxiliary on the composition and food of above-mentioned lower hyperlipidemia, hypertension, hyperglycemia
Material.
In a preferred embodiment, auxiliary material is additive, such as: mogroside, antierythrite etc..
In a preferred embodiment, the type of the health food is lozenge, chewable tablets or solid beverage.
Lozenge, chewable tablets or solid beverage are prepared into using common process known to those skilled in the art.
Above-mentioned health food has the function of lowering blood pressure and blood fat and hypoglycemic.
It is described in detail below with reference to specific embodiment.
Embodiment 1
The component of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is weighed by the parts by weight in table 1:
Table 1
| Component | Parts by weight |
| Lactobacillus acidophilus | 1 |
| Bifidobacterium lactis | 1 |
| The newborn polypeptide of peace benefit | 12.75 |
| Balsam pear wins peptide | 1 |
| Galactooligosaccharide | 61.5 |
| Oligofructose | 20.55 |
Then the above-mentioned raw materials in addition to strain are dried under the conditions of 60 DEG C to its moisture content respectively and is lower than 3%, cross 60
Mesh obtains screening object, then will screen object and the lactobacillus acidophilus weighed up, bifidobacterium lactis mix, lower hyperlipidemia, hypertension, hyperglycemia is prepared
Composition.Wherein, it is 4.2 × 10 that lactobacillus acidophilus, which contains viable count,9CFU/g, it is 5.8 that the bifidobacterium lactis, which contains viable count,
×109CFU/g。
Embodiment 2
The component of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is weighed by the parts by weight in table 2:
Table 2
| Component | Parts by weight |
| Lactobacillus acidophilus | 1 |
| Lactobacillus paracasei | 1 |
| Bifidobacterium lactis | 1 |
| The newborn polypeptide of peace benefit | 12.75 |
| Oligofructose | 20.55 |
| Galactooligosaccharide | 61.5 |
| Balsam pear powder | 1 |
| Balsam pear wins peptide | 1 |
| Steviol glycoside | 0.2 |
Then the above-mentioned raw materials in addition to strain are dried under the conditions of 60 DEG C to its moisture content respectively and is lower than 3%, cross 52
Mesh obtains screening object, then will screen object and mixes with lactobacillus acidophilus, lactobacillus paracasei and the bifidobacterium lactis weighed up, system
It is standby to obtain the composition of lower hyperlipidemia, hypertension, hyperglycemia.Wherein, it is 4.2 × 10 that the lactobacillus acidophilus, which contains viable count,9CFU/g, the cream bifid
It is 5.8 × 10 that bacillus, which contains viable count,9CFU/g, the lactobacillus paracasei contain viable count 8.2 × 109CFU/g。
Embodiment 3
The component of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is weighed by the parts by weight in table 3:
Table 3
Then the above-mentioned raw materials in addition to strain are dried under the conditions of 60 DEG C to its moisture content respectively and is lower than 3%, cross 52
Mesh obtains screening object, then will screen object and mixes with lactobacillus acidophilus, lactobacillus paracasei and the bifidobacterium lactis weighed up, system
It is standby to obtain the composition of lower hyperlipidemia, hypertension, hyperglycemia.Wherein, it is 5.0 × 10 that lactobacillus acidophilus, which contains viable count,9CFU/g, the bifidobacterium lactis
It is 7.0 × 10 containing viable count9CFU/g, the lactobacillus paracasei contain viable count 8.9 × 109CFU/g。
Embodiment 4
The component of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is weighed by the parts by weight in table 4:
Table 4
| Component | Parts by weight |
| Lactobacillus acidophilus | 1 |
| Lactobacillus paracasei | 1 |
| Bifidobacterium lactis | 1 |
| The newborn polypeptide of peace benefit | 10.75 |
| Oligofructose | 20.55 |
| Galactooligosaccharide | 61.5 |
| Balsam pear powder | 1 |
| Balsam pear wins peptide | 1 |
| Steviol glycoside | 0.2 |
Then the above-mentioned raw materials in addition to strain are dried under the conditions of 60 DEG C to its moisture content respectively and is lower than 3%, cross 52
Mesh obtains screening object, then will screen object and mixes with lactobacillus acidophilus, lactobacillus paracasei and the bifidobacterium lactis weighed up, system
It is standby to obtain the composition of lower hyperlipidemia, hypertension, hyperglycemia.Wherein, it is 5.0 × 10 that lactobacillus acidophilus, which contains viable count,9CFU/g, the bifidobacterium lactis
It is 7.0 × 10 containing viable count9CFU/g, the lactobacillus paracasei contain viable count 9.3 × 109CFU/g。
Comparative example 1
The preparation of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is substantially same as Example 1, and the composition of lower hyperlipidemia, hypertension, hyperglycemia is made.
The difference is that: the component of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is weighed by following weight parts:
Comparative example 2
The preparation of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is substantially same as Example 1, and lower hyperlipidemia, hypertension, hyperglycemia composition is made.No
Be with place: the component of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is weighed by following weight parts:
Comparative example 3
The preparation of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is substantially same as Example 1, and the composition of lower hyperlipidemia, hypertension, hyperglycemia is made.
The difference is that: the component of the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention is weighed by following weight parts:
Effect assessment
(1) experimental animal grouping and administration
The rat that weight is 190 ± 2g is chosen, rat is randomly divided into blank group, experimental group and control group, wherein experiment
Group is divided into 8 groups, respectively corresponds embodiment group and comparative example group, and every group rat 10.Blank group food sanitation standard diet, and lead to daily
Crossing oral gavage, to give 37 DEG C of warm waters appropriate；Experimental group eats high fat diet, and (rat that fat content is 59.3% is raised
Material), and the lower hyperlipidemia, hypertension, hyperglycemia group in daily stomach-filling embodiment (embodiment 1 to embodiment 4) and comparative example (comparative example 1 to comparative example 3)
Polymer solution, the composition solution are prepared as concentration using 37 DEG C of warm waters as solvent as 100mg/kg, each stomach-filling 0.5mL,
Oral administration gavage, control rats equally eat high fat diet identical with experimental group, give 37 by oral gavage daily
DEG C warm water is appropriate.Experiment in 12 weeks is carried out, at the end of experiment periods (12 week last day), Rat Fast is overnight.
(2) measurement of rat body weight, blood pressure, liver weight and tissue
At the beginning and end of experiment, the rat body weight in all groups is recorded respectively, and around-France measurement rat is covered using tail portion
Blood pressure at the end of experiment, passes through CO2After anesthesia is put to death animal 8 hours in the fasted state, blood sample is collected by cardiac puncture
Product, and centrifugation 10min is carried out with 4000 turns/min at -4 DEG C, weigh liver and tissue sample and with cryosel water washing.
(3) measurement of biochemical parameter
Using Automatic Clinical Analyzer analysis serum biochemical parameters, including triglycerides (TG), cholesterol etc., blood glucose is used
Instrument measures serum glucose concentration, measures insulin level in serum using business rat insulin ELISA kit.Wherein,
Systolic pressure and the difference of diastolic pressure are blood pressure, adipose tissue and weight ratio, liver and weight ratio, total cholesterol concentration and glycerol three
Ester, LDL/HDL ratio are used to measure blood lipids index, and the content of insulin and glucose is used to measure blood glucose target.
It the results are shown in Table 5 and table 6:
Table 5
Table 6
Systolic pressure and the difference of diastolic pressure are blood pressure, adipose tissue and weight ratio, liver and weight ratio, total cholesterol concentration
It is used to measure blood lipids index with triglycerides, LDL/HDL ratio, the content of insulin and glucose is used to measure blood glucose target.
By table 5 and table 6 it is found that the rat body weight in embodiment 1 to embodiment 4 group increases, show rat health status
Well.For blood glucose (insulin and glucose) inspection target, the corresponding index of rat is opposite in embodiment 1 to embodiment 4
In comparative example 1 (without lactobacillus acidophilus and bifidobacterium lactis), comparative example 2 (winning peptide without balsam pear), comparative example 3 (match by each component
It is more different from proportion of the invention than relationship) and control group for, reduced.Wherein, embodiment 2 is substantially reduced than control group
(P < 0.05).With regard to blood lipids index (adipose tissue and weight ratio, liver and weight ratio, total cholesterol concentration and triglycerides, LDL/
HDL ratio) for, the corresponding index of rat is (double without lactobacillus acidophilus and cream relative to comparative example 1 in embodiment 1 to embodiment 4
Discrimination bacillus), comparative example 2 (without balsam pear win peptide), comparative example 3 (each component proportion relation is different from proportion of the invention) and compare
For group, reduced.Wherein, embodiment 2 substantially reduces (P < 0.05) than control group.For blood markers, embodiment
1 into embodiment 4 rat corresponding index relative to comparative example 1 (without lactobacillus acidophilus and bifidobacterium lactis), comparative example 2
For (winning peptide without balsam pear), comparative example 3 (each component proportion relation is different from proportion of the invention) and control group, subtracted
It is few.Wherein, embodiment 2 substantially reduces (P < 0.05) than control group.
It can be seen that each group distribution ratio is reasonable in the composition of lower hyperlipidemia, hypertension, hyperglycemia of the invention, each component is indispensable, component it
Between synergistic effect the effect of can playing composition.That is, the composition of lower hyperlipidemia, hypertension, hyperglycemia of the present invention can effectively prevent
With reduction hypertension, the symptom of hyperlipidemia and hyperglycemia.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to guarantor of the invention
Protect range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Claims (10)
1. a kind of composition of lower hyperlipidemia, hypertension, hyperglycemia, which is characterized in that the raw material components including following parts by weight:
Wherein, strain includes 1-6 parts of lactobacillus acidophilus, 1-6 parts of bifidobacterium lactis.
2. the composition of lower hyperlipidemia, hypertension, hyperglycemia according to claim 1, which is characterized in that further include the raw material group of following parts by weight
Point:
The strain further include 1-6 parts of lactobacillus paracasei,
1-5 parts of balsam pear powder,
And 0.1-1 parts of steviol glycoside.
3. the composition of lower hyperlipidemia, hypertension, hyperglycemia according to claim 2, which is characterized in that the work contained in the lactobacillus paracasei
Bacterium number 7.0 × 109-9.5×109CFU/g。
4. the composition of lower hyperlipidemia, hypertension, hyperglycemia according to any one of claim 1-3, which is characterized in that the prebiotics are selected from low
One or both of poly- galactolipin and oligofructose.
5. the composition of lower hyperlipidemia, hypertension, hyperglycemia according to any one of claim 1-3, which is characterized in that in the lactobacillus acidophilus
The viable count contained is 3.0 × 109-5.5×109CFU/g, the viable count contained in the bifidobacterium lactis are 5.0 × 109-
7.5×109CFU/g。
6. a kind of preparation method of the composition of lower hyperlipidemia, hypertension, hyperglycemia of any of claims 1-5, which is characterized in that including with
Lower step:
Each raw material is taken according to corresponding parts by weight；
Other each raw materials in addition to strain are sieved respectively and obtain screening object；
It will screening object and strain mixing.
7. the preparation method of the composition of lower hyperlipidemia, hypertension, hyperglycemia according to claim 6, which is characterized in that the sieving referred to
50-70 mesh, interception partial size are less than the screening object of 50-70 mesh.
8. the preparation method of the composition of lower hyperlipidemia, hypertension, hyperglycemia according to claim 6, which is characterized in that before sieving, further include
Other each raw materials in addition to strain are dry at 50 DEG C -70 DEG C, the moisture content in other each raw materials in addition to strain
Lower than 3%.
9. a kind of health food, which is characterized in that composition and food including lower hyperlipidemia, hypertension, hyperglycemia as described in any one in claim 1-5
Acceptable auxiliary material on product.
10. health food according to claim 9, which is characterized in that the type of the health food is lozenge, chewable tablets
Or solid beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811125403.3A CN109259243A (en) | 2018-09-26 | 2018-09-26 | Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811125403.3A CN109259243A (en) | 2018-09-26 | 2018-09-26 | Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109259243A true CN109259243A (en) | 2019-01-25 |
Family
ID=65197760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811125403.3A Pending CN109259243A (en) | 2018-09-26 | 2018-09-26 | Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109259243A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111000246A (en) * | 2019-12-27 | 2020-04-14 | 汤臣倍健股份有限公司 | Probiotic dietary fiber composition for assisting in reducing triglyceride, application thereof and health-care product |
| CN113197288A (en) * | 2020-08-31 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof |
| CN114634892A (en) * | 2022-03-24 | 2022-06-17 | 浙江省农业科学院 | Probiotics composition with blood fat reducing function, preparation method and equipment |
| CN114984196A (en) * | 2022-06-30 | 2022-09-02 | 北京悦意时光生物科技有限公司 | Natural plant composition for preventing and treating arteriosclerosis, preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458415A (en) * | 2009-06-19 | 2012-05-16 | 丹尼斯科公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104055012A (en) * | 2014-05-29 | 2014-09-24 | 胡安然 | Microecologic preparation for preventing and curing hyperlipemia |
| CN104887716A (en) * | 2014-03-07 | 2015-09-09 | 景岳生物科技股份有限公司 | Lactobacillus reuteri GMNL-89 composition for treating type II diabetes mellitus and use thereof |
| CN105707863A (en) * | 2016-03-10 | 2016-06-29 | 劲膳美生物科技股份有限公司 | Blood fat-reducing medical science formula food |
| CN105769928A (en) * | 2016-03-25 | 2016-07-20 | 江南大学 | Application of clostridium butyrate in preparation for prevention and treatment or adjuvant therapy of hyperglycemia |
-
2018
- 2018-09-26 CN CN201811125403.3A patent/CN109259243A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458415A (en) * | 2009-06-19 | 2012-05-16 | 丹尼斯科公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104770739A (en) * | 2009-06-19 | 2015-07-15 | 杜邦营养生物科学有限公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104784694A (en) * | 2009-06-19 | 2015-07-22 | 杜邦营养生物科学有限公司 | Bifidobacteria for treating diabetes and related conditions |
| CN104887716A (en) * | 2014-03-07 | 2015-09-09 | 景岳生物科技股份有限公司 | Lactobacillus reuteri GMNL-89 composition for treating type II diabetes mellitus and use thereof |
| CN104055012A (en) * | 2014-05-29 | 2014-09-24 | 胡安然 | Microecologic preparation for preventing and curing hyperlipemia |
| CN105707863A (en) * | 2016-03-10 | 2016-06-29 | 劲膳美生物科技股份有限公司 | Blood fat-reducing medical science formula food |
| CN105769928A (en) * | 2016-03-25 | 2016-07-20 | 江南大学 | Application of clostridium butyrate in preparation for prevention and treatment or adjuvant therapy of hyperglycemia |
Non-Patent Citations (1)
| Title |
|---|
| 夏薇: ""全方位服务用户,打造"精准、营养"的健康生活——访上海诚一食品原料有限公司董事长李泼", 《食品安全导刊》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111000246A (en) * | 2019-12-27 | 2020-04-14 | 汤臣倍健股份有限公司 | Probiotic dietary fiber composition for assisting in reducing triglyceride, application thereof and health-care product |
| CN113197288A (en) * | 2020-08-31 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Probiotic composition for improving sugar tolerance and triglyceride level and preparation method thereof |
| CN114634892A (en) * | 2022-03-24 | 2022-06-17 | 浙江省农业科学院 | Probiotics composition with blood fat reducing function, preparation method and equipment |
| CN114984196A (en) * | 2022-06-30 | 2022-09-02 | 北京悦意时光生物科技有限公司 | Natural plant composition for preventing and treating arteriosclerosis, preparation method and application |
| CN114984196B (en) * | 2022-06-30 | 2023-01-06 | 北京悦意时光生物科技有限公司 | Natural plant composition for preventing and treating arteriosclerosis, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11723943B2 (en) | Therapeutic use of chardonnay seed products | |
| CN109259243A (en) | Composition of lower hyperlipidemia, hypertension, hyperglycemia and its preparation method and application | |
| US6869621B2 (en) | Diet composition comprising raw foods and dietary fibers | |
| Alam et al. | Development of fiber enriched herbal biscuits: a preliminary study on sensory evaluation and chemical composition | |
| JP5109117B2 (en) | Sudachi-derived composition, and pharmaceutical composition, health food and drink and supplement containing the composition | |
| CN108936698A (en) | Weight management composition and its related weight-reducing food product | |
| CN102266058B (en) | Yam and hawthorn lipid-lowering nutritional tablets | |
| Quek et al. | Impact of protein-rich meals on glycaemic response of rice | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| Yampolsky et al. | Kiwi (lat. Actinidia chinensis) | |
| KR102136886B1 (en) | Composition for prevention and treatment of muscular disorders or improvement of muscular functions comprising functional fermented material using oyster | |
| US9750272B2 (en) | Meal intended for human consumption | |
| WO2012026575A1 (en) | Muscle-enhancing agent | |
| WO2005082390A1 (en) | Fat accumulation inhibitors | |
| JP2008074735A (en) | Composition having inhibitory action on lipase and fat absorption inhibitor comprising the same as active ingredient | |
| RU2289951C1 (en) | Method for sambook production | |
| CN108430580B (en) | Method of inducing satiety | |
| CN1062424C (en) | Alpha-pumpkin corn powder | |
| JP2019127439A (en) | Supplement comprising morus alba leaves | |
| JP2006076954A (en) | Antiobestic agent, blood cholesterol level elevation inhibitor, and food and drink | |
| Desjardins | It's not a gut feeling-fruit and vegetables do have prebiotic-like effects | |
| CN109172805A (en) | A kind of plant extraction essence freeze-dried powder and its manufacture craft | |
| JP2012162472A (en) | Lipid eliminant | |
| JP2004033170A (en) | Health food product | |
| CA2182122A1 (en) | Dietary fiber supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190125 |